Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that TRAIL could induce PARP-1 cleavage and apoptosis in colon cancer HCT116 cell, but HT-29 cell was not sensitive to TRAIL.
|
31558316 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the combination of 3-BP and TRAIL can be a promising therapeutic strategy for treatment of colon cancer.
|
31491344 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we analyzed side by side apoptotic and non-apoptotic signaling induced by TRAIL or the agonistic TRAIL-R-specific antibodies Mapatumumab (anti-TRAIL-R1) and Lexatumumab (anti-TRAIL-R2) in the two isogenic colon carcinoma cell lines HCT116 p53+/+ and p53-/-.
|
30947287 |
2019 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vivo pathogenesis of colon carcinoma and its suppression by hydrophilic fractions of Clematis flammula via activation of TRAIL death machinery (DRs) expression.
|
30551475 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that the increased BECN1 accompanied by enhanced autophagy activity is responsible for the TRAIL resistance, and a combination of TRAIL with a PIK3C3-BECN1 inhibitor is a promising therapeutic approach for the treatment of colon cancer.
|
31092562 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lactobacillus casei Exerts Anti-Proliferative Effects Accompanied by Apoptotic Cell Death and Up-Regulation of TRAIL in Colon Carcinoma Cells.
|
26849051 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that gefitinib and TRAIL in combination produce a potent synergistic effect on TRAIL-sensitive human colon cancer HCT116 cells and an additive effect on TRAIL-resistant HT-29 cells.
|
27629794 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we have tested LUV-TRAIL in several human colon cancer cell lines with different sensitivity to sTRAIL.
|
27725224 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Niacin alleviates TRAIL-mediated colon cancer cell death via autophagy flux activation.
|
26517672 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation.
|
27421828 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRAIL is pro-apoptotic on colon cancer cells, while not cytotoxic towards normal healthy cells.
|
26771233 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we established a TRAIL-resistant human colon cancer DLD-1 cell line to clarify the mechanisms of TRAIL-resistance and developed agents to cancel its machinery.
|
26304927 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL.
|
25672292 |
2015 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, knockdown of survivin sensitized colon cancer cells to resistant of TRAIL-induced apoptosis.
|
26063410 |
2015 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.
|
25113506 |
2014 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we attempted to develop a multimodality approach using chemotherapeutic agent mitomycin C, biologic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L), and mild hyperthermia to treat colon cancer.
|
25156145 |
2014 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
|
23732517 |
2013 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we engineered murine MSCs (mMSCs) to express a secreted form of the TNF-related apoptosis-inducing ligand (TRAIL), which is a potent inducer of apoptosis in tumor cells, and tested these MSCs, termed MSC.sTRAIL, in combination with conventional chemotherapeutic drug treatment in colon cancer models.
|
23429289 |
2013 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Colon cancer (HCT116, SW480), prostate cancer (PC3, LNCaP) and leukemia (K562) cells were treated with STI571 and TRAIL.
|
22462553 |
2012 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of silibinin and TRAIL in an in vitro model of human colon cancer progression, consisting of primary colon tumor cells (SW480) and their derived TRAIL-resistant metastatic cells (SW620).
|
22555452 |
2012 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, Verticillin A effectively sensitized metastatic human colon carcinoma xenograft to TRAIL-mediated growth inhibition in vivo.
|
21911457 |
2011 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we showed the differential TRAIL responsiveness of human prostate adenocarcinoma PC3 and human colon carcinoma KM12 cells and their respective highly metastatic PC3-MM2 and KM12L4A sublines and investigated the mechanism underlying high susceptibility of human metastatic cancer cells to TRAIL.
|
21513580 |
2011 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The in vivo capability of 2-14 to sensitize colon cancer cells to TRAIL-induced apoptosis was evaluated in a syngenic colon cancer model in which CT26-derived grafts were induced in mice.
|
21817114 |
2011 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we sought to further confirm the antitumor activity of oncolytic virus-armed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy in xenografts, which derived from the tumors of patients with colon cancer.
|
21183948 |
2011 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells.
|
20661477 |
2010 |